Page 25 - Slide 1

Acute COVID-19
Localized Low-Risk PC Phase Guidance

(very-low, low- and favorable-intermediate risk [FIR])

Source Guidance

CUOG-CUA General
(Kokorovic et al. • In-person consult not recommended
Can Urol Assoc J. 2020) • Diagnostic investigations (imaging, biopsy) not recommended

Patients on or choosing active surveillance

• Short-term suspension of active surveillance where appropriate, including in-
person clinic visits, DRE, PSA, imaging, repeat biopsy

Patients choosing RP or RT
• Consider delay of RP/RT
• Do not use NADT to bridge the COVID-19

Patients on ongoing surveillance following definitive therapy

• Consider decreasing frequency of PSA testing and deferring in-office
appointments, particularly for patients >1 year since surgery or RT

ADT = androgen deprivation therapy; DRE = digital rectal exam; NADT = neoadjuvant androgen deprivation therapy; PC = prostate cancer; PSA = prostate-specific antigen; RP = radical prostatectomy; RT = radiation therapy.
2525